Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

Abstract: Described herein are methods of separating lipid nanoparticles (LNPs) according to their isoelectic points, the methods comprising applying a separating voltage to a separation matrix comprising carrier ampholytes and the LNPs for a sufficient time to separate the LNPs according to their isoelectic points.

Abstract: A supercritical extractor system may include extractor chambers coupled to a supercritical fluid pump and configured to receive a matrix for an extraction process and a supercritical fluid from the supercritical fluid pump, and evaporator chambers coupled to the extractor chambers and configured to output an extractant from the matrix. Each evaporator chamber may include a body defining a cavity, a cone within the cavity, and arms coupled between an inner surface of the body and the cone. The supercritical extractor system may include a condenser coupled between the evaporator chambers and the supercritical fluid reservoir, and a controller coupled to the supercritical fluid pump, the extractor chambers, and the evaporator chambers and configured to monitor a characteristic during the extraction process.

Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods of using such antibodies in treating and diagnosing an MN-related disorder.

Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.

Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods for using such antibodies in treating and diagnosing an MN-related disorder.

Abstract: The present invention relates to crystals of the Escherichia coli MurG, a membrane-associated UDP-glycosyltransferase involved in peptidoglycan biosynthesis. The present invention also relates to three-dimensional atomic coordinates of the MurG protein, three-dimensional structures of the protein, and images thereof. The present invention relates to methods of crystallizing MurG proteins.

Abstract: The present invention relates to crystals of the Escherichia coli MurG, a membrane-associated UDP-glycosyltransferase involved in peptidoglycan biosynthesis. The present invention also relates to three-dimensional atomic coordinates of the MurG protein, three-dimensional structures of the protein, and images thereof. The present invention also relates to the atomic coordinates and three-dimensional structures of the &agr;-carbon backbone and of the &agr;-carbon backbone and conserved amino acid residue sidechains of the MurG protein and images thereof. The present invention further relates to three-dimensional atomic coordinates of the donor nucleotide binding site, the acceptor binding site, and the membrane association site of the MurG protein, three-dimensional structures of the binding domains, and images thereof. The present invention also relates to computer readable media encoded with sets of the three dimensional coordinates described herein.